Nitrogen And Carbonyl Or Cyano Bonded Directly To The Tetracyclo Ring System (e.g., Tetracycline, Etc.) Patents (Class 552/203)
-
Publication number: 20110207951Abstract: 7-substituted fused ring tetracycline compounds, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7-substituted fused ring tetracycline compounds are described.Type: ApplicationFiled: February 18, 2011Publication date: August 25, 2011Applicant: Paratek Pharmaceuticals, Inc.Inventors: Mark L. Nelson, Laura Honeyman
-
Patent number: 7943600Abstract: This invention provides methods and pharmaceutical compositions for treating a subject having a condition associated with an antibiotic resistant bacterial infection. The invention includes administering to a subject a therapeutically effective combination of an antibiotic and a toxic compound (e.g., a nucleic acid damaging agent, an alkylating agent, or a heavy metal containing compound).Type: GrantFiled: December 20, 2005Date of Patent: May 17, 2011Assignees: Massachusetts Institute of Technology, University of MassachusettsInventors: Doriana Froim, John M. Essigmann, Martin G. Marinus
-
Publication number: 20110086821Abstract: Methods and compositions for treating Cryptosporidium parvum related disorders in a mammal are discussed. Several novel tetracycline compounds useful for treating Cryptosporidium parvum related disorders are also included.Type: ApplicationFiled: October 4, 2010Publication date: April 14, 2011Applicant: Trustees of Tufts CollegeInventors: Stuart B. Levy, Mark L. Nelson
-
Publication number: 20110086822Abstract: The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.Type: ApplicationFiled: October 8, 2010Publication date: April 14, 2011Inventors: Mark L. Nelson, Kwasi Ohemeng, Roger Frechette, Paul Abato, Victor Amoo, Upul Bandarage, Joel Berniac, Beena Bhatia, Jackson Chen, Mohamed Y. Ismail, Oak Kim, Laura Honeyman, Rachid Mechiche, Andre Pearson, Laxma Reddy Nagavelli, Paul Sheahan, Atul K. Verma, Peter Viski, Tadeusz Warchol
-
Publication number: 20110077225Abstract: The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds such as blocking tetracycline efflux and modulation of gene expression.Type: ApplicationFiled: December 7, 2010Publication date: March 31, 2011Applicant: Paratek Pharmaceuticals, Inc.Inventors: Joel Berniac, Beena Bhatia, Mark Grier, Mark L. Nelson, Jingwen Pan
-
Patent number: 7893282Abstract: 7-substituted fused ring tetracycline compounds, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7-substituted fused ring tetracycline compounds are described.Type: GrantFiled: October 10, 2007Date of Patent: February 22, 2011Assignee: Paratek Pharmaceuticals, Inc.Inventors: Mark L. Nelson, Laura Honeyman
-
Publication number: 20110021466Abstract: The disclosure provides a method of reducing infarct size in the heart following permanent ischemia or ischemia/reperfusion (IR) event or method for delaying, attenuating or preventing adverse cardiac remodeling comprising administering a drug selected from the group consisting of epicatechin, derivatives thereof and pharmaceutically acceptable salts thereof, wherein the subject is a human or a veterinary animal. Additionally the disclosure provides a method of treating subarachnoid hemorrhage or atrial fibrillation or of enhancing or preserving migration, seeding, proliferation, differentiation and/or survival of stem cells in injured heart tissue comprising administering a drug selected from the group consisting of epicatechin, derivatives thereof and pharmaceutically acceptable salts thereof. The effects of epicatechin administration are sustained over time.Type: ApplicationFiled: March 12, 2009Publication date: January 27, 2011Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Francisco Villarreal, Katrina Go Yamazaki, Pam Rajendran Taub, Alan Maisel
-
Publication number: 20110009371Abstract: The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among many organisms previously susceptible to tetracycline antibiotics. The modular synthesis of tetracyclines and tetracycline analogs described provides an efficient and enantioselective route to a variety of tetracycline analogs and polycyclines previously inaccessible via earlier tetracycline syntheses and semi-synthetic methods. These analogs may be used as anti-microbial agents or anti-proliferative agents in the treatment of diseases of humans or other animals.Type: ApplicationFiled: May 12, 2010Publication date: January 13, 2011Inventors: Andrew G. Myers, Mark G. Charest, Christian D. Lerner, Jason D. Brubaker, Dionicio R. Siegel
-
Patent number: 7851460Abstract: 7-phenyl-substituted tetracycline compounds, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7-phenyl-substituted tetracycline compounds are described.Type: GrantFiled: April 17, 2009Date of Patent: December 14, 2010Assignee: Trustees of Tufts CollegeInventors: Mark L. Nelson, Glen Rennie, Darrell Koza
-
Publication number: 20100305309Abstract: The present invention provides various functionalized nanodiamond particles. In particular, the present invention provides soluble complexes of nanodiamond particles and therapeutic agents, for example insoluble therapeutics, anthracycline and/or tetracycline compounds, nucleic acids, proteins, etc.Type: ApplicationFiled: May 28, 2010Publication date: December 2, 2010Applicant: Northwestern UniversityInventors: Dean Ho, Mark Chen, Erik Pierstorff, Erik Robinson, Robert Lam, Rafael Shimkunas, Xueqing Zhang
-
Publication number: 20100305072Abstract: The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms.Type: ApplicationFiled: December 21, 2007Publication date: December 2, 2010Inventors: Oak K. Kim, Mark L. Nelson, Paul Abato, Haregewein Assefa, Joel Bernaiac, Mohamed Y. Ismail, Todd Bowser, Mark Grier, Beena Bhatia, Atul K. Verma, Laura Honeyman, Jingwen Pan
-
Publication number: 20100291622Abstract: The present invention provides compounds which exhibit an inhibitory effect on undecaprenyl diphosphate synthase of microbes and thereby they are expected to be used clinically as pharmaceutical agents for infectious diseases caused by bacteria. The process comprises culturing a microbe belonging to Penicillium and having ability of producing an FKI-3368 substance in or on a nutrient medium to accumulate the FKI-3368 substance in the nutrient medium and collecting the FKI-3368 substance from the culture.Type: ApplicationFiled: September 12, 2008Publication date: November 18, 2010Applicant: SCHOOL JURIDICAL PERSON KITASATO INSTITUTEInventors: Hiroshi Tomoda, Junji Inokoshi, Rokuro Masuma, Satoshi Omura
-
Publication number: 20100292183Abstract: Provided herein are methods and compositions for the in vitro formation of tetracycline conjugates, for example, tetracycline conjugated to anti-coagulants. The present invention also provides methods for preventing or treating plaque-related diseases or disorders such as atherosclerosis using tetracycline alone, or the tetracycline conjugates of the present invention.Type: ApplicationFiled: May 14, 2010Publication date: November 18, 2010Inventor: Shanmugavel MADASAMY
-
Patent number: 7825105Abstract: The present invention pertains to novel 3, 10, and/or 12a-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.Type: GrantFiled: February 28, 2005Date of Patent: November 2, 2010Assignee: Paratek Pharmaceuticals, Inc.Inventors: Upul Bandarage, Mohamed Y. Ismail, Mark L. Nelson
-
Patent number: 7820641Abstract: The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.Type: GrantFiled: December 18, 2003Date of Patent: October 26, 2010Assignee: Paratek Pharmaceuticals, Inc.Inventors: Mark L. Nelson, Peter Viski, Jackson Chen, Tadeusz Warchol
-
Patent number: 7812008Abstract: This invention provides compounds of Formula (I); or a tautomer or pharmaceutically acceptable salts thereof useful as antibacterial agents.Type: GrantFiled: February 14, 2006Date of Patent: October 12, 2010Assignee: Wyeth LLCInventors: Phaik-Eng Sum, Tarek Mansour
-
Patent number: 7803903Abstract: The invention relates to low-molecular doxorubicin peptide derivatives containing MMP-2 or MMP-9 divisible peptide sequences and a protein-binding group.Type: GrantFiled: March 4, 2004Date of Patent: September 28, 2010Assignee: KTB Tumorforschungs GmbHInventor: Felix Kratz
-
Publication number: 20100190756Abstract: The present invention pertains to novel 3, 10, and/or 12a-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.Type: ApplicationFiled: March 18, 2010Publication date: July 29, 2010Applicant: Paratek Pharmaceuticals, Inc.Inventors: Upul Bandarage, Jackson Chen, Mohamed Y. Ismail, Mark L. Nelson, Kwasi Ohemeng
-
Publication number: 20100160263Abstract: The present invention pertains to novel 7,9-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.Type: ApplicationFiled: November 12, 2009Publication date: June 24, 2010Applicant: Paratek Pharmaceuticals, Inc.Inventors: Mark L. Nelson, Roger Frechette, Peter Viski, Mohamed Ismail, Todd Bowser, Laura McIntyre, Beena Bhatia, Paul Hawkins, Laxma Reddy Nagavelli, Karen Stepleton, Tad Warchol, Paul Sheahan
-
Publication number: 20100160265Abstract: 7, 8 and 9-substituted tetracycline compounds, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7, 8 and 9-substituted tetracycline compounds are described.Type: ApplicationFiled: March 9, 2010Publication date: June 24, 2010Applicant: Trustees of Tufts CollegeInventors: Mark L. Nelson, Darrell J. Koza, Glen Rennie
-
Patent number: 7705168Abstract: Disclosed herein is a manufacturing process for the preparation of tigecycline suitable for intravenous infusion.Type: GrantFiled: June 16, 2006Date of Patent: April 27, 2010Assignee: Wyeth LLCInventors: Gurmukh Chanana, Dominic Ventura, Richard Saunders, Mahdi B. Fawzi
-
Patent number: 7696186Abstract: The present invention pertains to novel 7,9-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.Type: GrantFiled: December 16, 2003Date of Patent: April 13, 2010Assignee: Paratek Pharmaceuticals, Inc.Inventors: Mark L. Nelson, Roger Frechette, Peter Viski, Mohamed Y. Ismail, Todd Bowser, Laura McIntyre, Beena Bhatia, Paul Hawkins, Laxma Reddy, Karen Stapleton, Tadeusz Warchol, Paul Sheahan
-
Patent number: 7696187Abstract: The present invention relates to 9-substituted tetracycline derivatives as well as compositions and use thereof.Type: GrantFiled: March 28, 2006Date of Patent: April 13, 2010Assignee: Trustees of Tufts CollegeInventors: Mark L. Nelson, Glen Rennie, Darrell J. Koza
-
Patent number: 7696188Abstract: 7, 8 and 9-substituted tetracycline compounds, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7, 8 and 9-substituted tetracycline compounds are described.Type: GrantFiled: March 4, 2008Date of Patent: April 13, 2010Assignee: Trustees of Tufts CollegeInventors: Mark L. Nelson, Darrell J. Koza, Glen Rennie
-
Patent number: 7652002Abstract: A compound of formula (I):Type: GrantFiled: December 20, 2006Date of Patent: January 26, 2010Assignee: Paratek Pharmaceuticals, Inc.Inventors: Carmen García-Luzón, Juan Carlos Cuevas, Jose M. Fiandor, Araceli Mallo, Mark L. Nelson, Roger Frechette
-
Publication number: 20100004211Abstract: 7-substituted tetracycline compounds, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7-substituted tetracycline compounds are described.Type: ApplicationFiled: January 21, 2009Publication date: January 7, 2010Inventors: Mark L. Nelson, Darrell J. Koza
-
Publication number: 20090306022Abstract: The present invention pertains, at least in part, to novel 7-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.Type: ApplicationFiled: June 9, 2009Publication date: December 10, 2009Applicants: Trustees of Tufts College, Paratek Pharmaceuticals, Inc.Inventors: Mark L. Nelson, Roger Frechette, Peter Viski, Mohamed Ismail, Todd Bowser, Beena Bhatia, David Messersmith, Laura McIntyre, Darrell Koza, Glen Rennie, Paul Sheahan, Paul Hawkins, Atul Verma, Tadeusz Warchol, Upul Bandarage
-
Publication number: 20090258842Abstract: 7-phenyl-substituted tetracycline compounds, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7-phenyl-substituted tetracycline compounds are described.Type: ApplicationFiled: April 17, 2009Publication date: October 15, 2009Applicant: Trustees of Tufts CollegeInventors: Mark L. Nelson, Glen Rennie, Darrell Koza
-
Patent number: 7595309Abstract: The present invention pertains, at least in part, to novel 7-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.Type: GrantFiled: May 24, 2004Date of Patent: September 29, 2009Assignees: Trustees of Tufts College, Paratek Pharmaceuticals, Inc.Inventors: Mark L. Nelson, Roger Frechette, Peter Viski, Beena Bhatia, David Messersmith, Mohamed Y. Ismail, Todd Bowser, Laura McIntyre, Darrell J. Koza, Glen Rennie, Paul Sheahan, Paul Hawkins, Atul K. Verma, Tadeusz Warchol, Upul Bandarage
-
Publication number: 20090131696Abstract: The present invention provides an improved methodology by which therapeutically to overcome resistance to tetracycline in living cells including bacteria, parasites, fungi, and rickettsiae. The methodology employs a blocking agent such as C5 ester derivatives, or 6-deoxy 13-(substituted mercapto) derivatives of tetracycline, in combination with other tetracycline-type antibiotics as a synergistic combination of compositions to be administered simultaneously, sequentially or concurrently. In another embodiment, certain novel compositions are provided which may be administered alone against, for example, a sensitive or resistant strain of gram positive bacteria such as S. aureus and E. faecalis. The concomitantly administered compositions effectively overcome the tetracycline resistant mechanisms present such that the cell is effectively converted from a tetracycline-resistant state to a tetracycline-sensitive state.Type: ApplicationFiled: August 19, 2008Publication date: May 21, 2009Applicant: Trustees of Tufts CollegeInventor: Stuart B. Levy
-
Patent number: 7521437Abstract: 7-phenyl-substituted tetracycline compounds, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7-phenyl-substituted tetracycline compounds are described.Type: GrantFiled: February 13, 2007Date of Patent: April 21, 2009Assignee: Trustees of Tufts CollegeInventors: Mark L. Nelson, Glen Rennie, Darrell J. Koza
-
Publication number: 20090054312Abstract: Methods are provided for screening for SMIPs (small molecule inhibitors of p27 depletion). The SMIPs thus identified are useful for treating cancers and other proliferative diseases.Type: ApplicationFiled: August 22, 2008Publication date: February 26, 2009Inventors: Dieter A. Wolf, Gregory P. Roth
-
Publication number: 20080306032Abstract: 7-phenyl-substituted tetracycline compounds which are substantially free of positional isomers, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7-phenyl-substituted tetracycline compounds are described. 7-substituted tetracycline compounds which are substantially free of positional isomers, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7-substituted tetracycline compounds are described.Type: ApplicationFiled: July 31, 2008Publication date: December 11, 2008Inventors: Mark L. Nelson, Mohamed Y. Ismail
-
Publication number: 20080167273Abstract: 7, 8 and 9-substituted tetracycline compounds, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7, 8 and 9-substituted tetracycline compounds are described.Type: ApplicationFiled: March 4, 2008Publication date: July 10, 2008Applicant: Trustees of Tufts CollegeInventors: Mark L. Nelson, Darrell J. Koza, Glen Rennie
-
Patent number: 7214669Abstract: A treatment for inhibiting microbial or tumor growth is disclosed, which comprises adding to a subject in need of treatment an effective amount of one or more tetracycline derivatives.Type: GrantFiled: October 4, 2002Date of Patent: May 8, 2007Assignee: Tetragenex Pharmaceuticals, Inc.Inventors: Joseph J. Hlavka, Richard J. Ablin
-
Patent number: 7208482Abstract: A compound of formula (I):Type: GrantFiled: August 6, 2003Date of Patent: April 24, 2007Assignee: Paratek Pharmaceuticals, Inc.Inventors: Carmen García-Luzón, Juan Carlos Cuevas, Jose M. Fiandor, Araceli Mallo, Mark L. Nelson, Roger Frechette
-
Patent number: 7067504Abstract: The present invention is a di-steroidal prodrug of ethinyl estradiol according to formula I:Type: GrantFiled: December 10, 2004Date of Patent: June 27, 2006Assignee: Warner Chilcott Company, Inc.Inventors: John Alexander King, James Keown, James William McIlroy, William Paul Armstrong, Michael Anthony McKervey, Austin McMordie
-
Patent number: 7067505Abstract: The present invention is a di-steroidal prodrug of estradiol having the following formula:Type: GrantFiled: December 10, 2004Date of Patent: June 27, 2006Assignee: Warner Chilcott Company, Inc.Inventors: John Alexander King, James Keown, James William McIlroy, William Paul Armstrong, Michael Anthony McKervey, Austin McMordie
-
Patent number: 7056902Abstract: The present invention pertains, at least in part, to novel substituted 4-dedimethylamino tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.Type: GrantFiled: January 6, 2003Date of Patent: June 6, 2006Assignee: Paratek Pharmaceuticals, Inc.Inventors: Mark L. Nelson, Kwasi Ohemeng
-
Patent number: 7001918Abstract: A compound of Formula (I): wherein variables R, R1, R2, R3 and A are as defined in theType: GrantFiled: June 1, 2004Date of Patent: February 21, 2006Assignee: Paratek Pharmaceuticals, Inc.Inventors: Sophie Huss, Jose M. Bueno, Jose M. Fiandor, Roger Frechette
-
Patent number: 6946453Abstract: The present invention provides new chemically modified 4-dedimethylaminotetracycline compounds that can be substituted with aryl, alkenyl, or alkynyl groups. The 7, 8, and/or 9 positions and methods for preparing such compounds. Other tetracycline compounds include the 4-dedimethylaminotetracycline derivatives with an oxime group, NH-Alkyl, or N—NH-Alkyl group substituted at the C4 position as well as C2 Mannich derivatives. The present invention also provides a method of treating a mammal suffering from conditions or diseases by administering to the mammal an effective amount of the new chemically modified tetracycline compounds.Type: GrantFiled: October 18, 2002Date of Patent: September 20, 2005Assignee: CollaGenex Pharmaceuticals, Inc.Inventors: Robert A. Ashley, Joseph J. Hlavaka
-
Patent number: 6894036Abstract: The present invention provides new chemically modified 4-dedimethylaminotetracycline compounds that can be substituted with aryl, alkenyl, or alkynyl groups. The 7, 8, and/or 9 positions and methods for preparing such compounds. Other tetracycline compounds include the 4-dedimethylaminotetracycline derivatives with an oxime group, NH-Alkyl, or N—NH-Alkyl group substituted at the C4 position as well as C2 Mannich derivatives. The present invention also provides a method of treating a mammal suffering from conditions or diseases by administering to the mammal an effective amount of the new chemically modified tetracycline compounds.Type: GrantFiled: June 10, 2003Date of Patent: May 17, 2005Assignee: CollaGenex Pharmaceuticals, IncorporatedInventors: Robert Ashley, Joseph J. Hlavka
-
Patent number: 6818635Abstract: The present invention pertains, at least in part, to novel 7-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.Type: GrantFiled: June 29, 2001Date of Patent: November 16, 2004Assignees: Paratek Pharmaceuticals, Inc., Trustees of Tufts CollegeInventors: Mark L. Nelson, Roger Frechette, Peter Viski, Beena Bhatia, David Messersmith
-
Publication number: 20040224928Abstract: The present invention pertains, at least in part, to novel 7-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.Type: ApplicationFiled: May 24, 2004Publication date: November 11, 2004Applicants: Trustees of Tufts College, Paratek Pharmaceuticals, Inc.Inventors: Mark L. Nelson, Roger Frechette, Peter Viski, Mohamed Ismail, Todd Bowser, Beena Bhatia, David Messersmith, Laura McIntyre, Darrell Koza, Glen Rennie, Paul Sheahan, Paul Hawkins, Atul Verma, Tadeusz Warchol, Upul Bandarage
-
Publication number: 20040214801Abstract: The present invention pertains, at least in part, to novel 9- substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.Type: ApplicationFiled: May 4, 2004Publication date: October 28, 2004Applicants: Paratek Pharmaceuticals, Inc., Trustees of Tufts CollegeInventors: Mark L. Nelson, Roger Frechette, Peter Viski, Mohamed Ismail, Todd Bowser, Jimmy Dumornay, Glen Rennie, Gui Liu, Darrell Koza, Paul Sheahan, Karen Stapleton, Paul Hawkins, Beena Bhatia, Atul K. Verma, Laura McIntyre, Tadeusz Warchol, David Messersmith
-
Publication number: 20040176334Abstract: Substituted tetracycline compounds, methods of synthesis, and methods of use are discussed. Tetracyclines useful for treating tetracycline related disorders are also discussed. Intermediates useful for synthesizing other tetracycline compounds are also included.Type: ApplicationFiled: February 24, 2004Publication date: September 9, 2004Applicants: Paratek Pharmaceuticals, Inc., Trustees of Tufts CollegeInventors: Mark L. Nelson, Stuart B. Levy, Roger Frechette, Todd E. Bowser, Mohamed Y. Ismail
-
Publication number: 20040138183Abstract: The present invention pertains to novel 7,9-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.Type: ApplicationFiled: December 16, 2003Publication date: July 15, 2004Applicant: Paratek Pharmaceuticals, Inc.Inventors: Mark L. Nelson, Roger Frechette, Peter Viski, Mohamed Y. Ismail, Todd Bowser, Laura McIntyre, Beena Bhatia, Paul Hawkins, Laxma Reddy, Karen Stapleton, Tadeusz Warchol, Paul Sheahan
-
Patent number: 6683068Abstract: The present invention pertains to novel 7,9-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.Type: GrantFiled: June 29, 2001Date of Patent: January 27, 2004Assignee: Paratek Pharmaceuticals, Inc.Inventors: Mark L. Nelson, Roger Frechette, Peter Viski, Mohamed Ismail, Todd Bowser, Laura McIntyre, Beena Bhatia, Paul Hawkins, Laxma Reddy, Karen Stapleton, Tad Warchol, Paul Sheahan
-
Publication number: 20040002481Abstract: The present invention provides new chemically modified 4-dedimethylaminotetracycline compounds that can be substituted with aryl, alkenyl, or alkynyl groups. The 7, 8, and/or 9 positions and methods for preparing such compounds. Other tetracycline compounds include the 4-dedimethylaminotetracycline derivatives with an oxime group, NH-Alkyl, or N-NH-Alkyl group substituted at the C4 position as well as C2 Mannich derivatives. The present invention also provides a method of treating a mammal suffering from conditions or diseases by administering to the mammal an effective amount of the new chemically modified tetracycline compounds.Type: ApplicationFiled: June 10, 2003Publication date: January 1, 2004Applicant: CollaGenex Pharmaceuticals, Inc.Inventors: Robert Ashley, Joseph J. Hlavka
-
Patent number: RE40183Abstract: The invention is drawn to 7-substituted-9-(substituted amino)-6-demethyl-6-deoxytetracycline compounds of the formula wherein R, X, R5 and R6 are defined in the specification. The compounds of the invention are useful as broad spectrum antibiotics.Type: GrantFiled: June 3, 2005Date of Patent: March 25, 2008Assignee: Wyeth Holdings CorporationInventors: Joseph J. Hlavka, Phaik-Eng Sum, Yakov Gluzman, Ving J. Lee, Adma A. Ross